1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue

 
• By Emily Hayes

Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.

Plastic Autoinjector_222700717_1200.jpg
Currently, rescue treatments for severe hypoglycemia need to be reconstituted, but prefilled syringes in autoinjectors may be on the way.

Positive Phase III results across the board for Zealand Pharma AS's dasiglucagon as a ready-to-use prefilled syringe rescue medication for severe hypoclyemia put the drug on track for a US FDA filing in the second half of 2019, but far behind two competing products that are already under review – Eli Lilly & Co.'s needle-free nasal product AMG504-1 and Xeris Pharmaceuticals Inc.'s XeriSol glucagon autoinjector.

Dasiglucagon (glucagon analog stable in liquid formulation) will be delivered in Zealand's ready-to-use HypoPal autoinjector rescue pen. Severe hypoglycemia is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total deal value of GLP-1-associated assets globally this year is already double that of the previous two years combined, with China-originated assets accounting for a substantial majority.

Discontinuations For Viking’s Oral Obesity Drug VK2735 Scare Investors

 
• By Joseph Haas

Analysts lauded the 13-week weight-reduction rates Viking’s oral dual GLP-1/GIP agonist showed in Phase II, but the firm’s stock tumbled 42% due to high discontinuation rates.

Wegovy’s Win In MASH Gives Novo A Much-Needed Edge Over Lilly

 
• By Manas Mishra

Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

More from Therapy Areas

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 
• By Andrew McConaghie

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag

 
• By Alaric DeArment

The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.

Wegovy’s Win In MASH Gives Novo A Much-Needed Edge Over Lilly

 
• By Manas Mishra

Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.